Traders should monitor upcoming clinical trial readouts and potential for rolling NDA submission; Fast Track status enhances the likelihood of accelerated approval, which could serve as a near-term catalyst for QNRX stock.
Price Chart
Executive Summary
Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation for QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare genetic skin disorder with no approved therapies. This designation may accelerate regulatory review and enables more frequent FDA interactions, supporting the company's late-stage clinical development program.
Key Facts
- FDA granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome
- QRX003 is in two late-stage whole-body clinical trials
- Previously received Orphan Drug Designation from both FDA and EMA, and Pediatric Rare Disease Designation from FDA
- No FDA-approved treatments currently exist for Netherton Syndrome
- Fast Track status allows for potential rolling review, Accelerated Approval, and Priority Review
Financial Impact
Non-dilutive regulatory catalyst with potential to increase valuation; Fast Track status reduces development risk and may shorten path to approval
Risk Factors
- Clinical trial results may not meet endpoints despite Fast Track status
- Regulatory approval is not guaranteed even with Fast Track Designation
- Company remains pre-revenue; valuation dependent on clinical and regulatory success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253756 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $3.90 (−10.55%) |
Sep 2, 2026 6w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $3.90 (−42.14%) |
Aug 28, 2026 7w ago | 8-K | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▼ −1.63% | ▼ −1.93% | $3.90 (+36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 20, 2026 8w ago | 8-K | $5.57 $5.42 | ▼ −2.69% | ▼ −2.40% | $3.90 (−29.98%) |
Aug 7, 2026 10w ago | Press Release | $4.79 $5.36 | ▲ +11.90% | ▲ +11.93% | $3.90 (−18.58%) |
Jun 23, 2026 16w ago | 8-K | $3.83 $4.20 | ▲ +9.66% | ▲ +9.52% | $3.90 (+1.83%) |
May 7, 2026 23w ago | Press Release | $6.37 $5.93 | ▼ −6.91% | ▼ −7.74% | $3.90 (−38.78%) |
May 5, 2026 23w ago | ANALYST-UPGRADE | $6.31 $6.43 | ▲ +1.90% | ▲ +0.52% | $3.90 (−38.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access